A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report
Abstract Background Spinal cord astrocytoma is a rare neoplasm, and patients usually recur within months after surgery. There is currently a lack of consensus regarding post-operative treatment. Clinical data on the activity of systemic treatment like chemoradiotherapy and anti-angiogenic agents als...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-07061-3 |
id |
doaj-d1d51d4000de44f09fe52b4cf7255961 |
---|---|
record_format |
Article |
spelling |
doaj-d1d51d4000de44f09fe52b4cf72559612020-11-25T03:01:04ZengBMCBMC Cancer1471-24072020-07-012011610.1186/s12885-020-07061-3A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case reportJietao Lin0Ling Yu1Yuanfeng Fu2Hanrui Chen3Xinting Zheng4Shutang Wang5Chan Gao6Yang Cao7Lizhu Lin8Oncology Center, the First Affiliated Hospital of Guangzhou University of Chinese MedicineOncology Center, the First Affiliated Hospital of Guangzhou University of Chinese MedicineShanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan UniversityOncology Center, the First Affiliated Hospital of Guangzhou University of Chinese MedicineOncology Center, the First Affiliated Hospital of Guangzhou University of Chinese MedicineOncology Center, the First Affiliated Hospital of Guangzhou University of Chinese MedicineMedical Affairs,3D Medicines Inc.Oncology Center, the First Affiliated Hospital of Guangzhou University of Chinese MedicineOncology Center, the First Affiliated Hospital of Guangzhou University of Chinese MedicineAbstract Background Spinal cord astrocytoma is a rare neoplasm, and patients usually recur within months after surgery. There is currently a lack of consensus regarding post-operative treatment. Clinical data on the activity of systemic treatment like chemoradiotherapy and anti-angiogenic agents also remained scant. Next-generation sequencing (NGS) -based genomic profiling thus may help identify potential treatment options for a subset of patients that harbor actionable genetic alterations. Case presentation We reported for the first time a refractory case of grade III spinal cord astrocytoma that underwent two surgeries but eventually progressed following post-operative chemoradiotherapy plus bevacizumab. Hybridization capture-based NGS using a 381-gene panel disclosed cyclin dependent kinase 4 (CDK4) amplification and after receiving a triplet regimen containg palbociclib for 15 months, the patient achieved complete response. Conclusions This case demonstrated the importance of genetic profiling and the benefit of a multi-modality treatment strategy in cancer management.http://link.springer.com/article/10.1186/s12885-020-07061-3Spinal astrocytomanext-generation sequencingPalbociclibTargeted therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jietao Lin Ling Yu Yuanfeng Fu Hanrui Chen Xinting Zheng Shutang Wang Chan Gao Yang Cao Lizhu Lin |
spellingShingle |
Jietao Lin Ling Yu Yuanfeng Fu Hanrui Chen Xinting Zheng Shutang Wang Chan Gao Yang Cao Lizhu Lin A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report BMC Cancer Spinal astrocytoma next-generation sequencing Palbociclib Targeted therapy |
author_facet |
Jietao Lin Ling Yu Yuanfeng Fu Hanrui Chen Xinting Zheng Shutang Wang Chan Gao Yang Cao Lizhu Lin |
author_sort |
Jietao Lin |
title |
A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report |
title_short |
A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report |
title_full |
A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report |
title_fullStr |
A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report |
title_full_unstemmed |
A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report |
title_sort |
refractory case of cdk4-amplified spinal astrocytoma achieving complete response upon treatment with a palbociclib-based regimen:a case report |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2020-07-01 |
description |
Abstract Background Spinal cord astrocytoma is a rare neoplasm, and patients usually recur within months after surgery. There is currently a lack of consensus regarding post-operative treatment. Clinical data on the activity of systemic treatment like chemoradiotherapy and anti-angiogenic agents also remained scant. Next-generation sequencing (NGS) -based genomic profiling thus may help identify potential treatment options for a subset of patients that harbor actionable genetic alterations. Case presentation We reported for the first time a refractory case of grade III spinal cord astrocytoma that underwent two surgeries but eventually progressed following post-operative chemoradiotherapy plus bevacizumab. Hybridization capture-based NGS using a 381-gene panel disclosed cyclin dependent kinase 4 (CDK4) amplification and after receiving a triplet regimen containg palbociclib for 15 months, the patient achieved complete response. Conclusions This case demonstrated the importance of genetic profiling and the benefit of a multi-modality treatment strategy in cancer management. |
topic |
Spinal astrocytoma next-generation sequencing Palbociclib Targeted therapy |
url |
http://link.springer.com/article/10.1186/s12885-020-07061-3 |
work_keys_str_mv |
AT jietaolin arefractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT lingyu arefractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT yuanfengfu arefractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT hanruichen arefractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT xintingzheng arefractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT shutangwang arefractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT changao arefractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT yangcao arefractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT lizhulin arefractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT jietaolin refractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT lingyu refractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT yuanfengfu refractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT hanruichen refractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT xintingzheng refractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT shutangwang refractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT changao refractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT yangcao refractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport AT lizhulin refractorycaseofcdk4amplifiedspinalastrocytomaachievingcompleteresponseupontreatmentwithapalbociclibbasedregimenacasereport |
_version_ |
1724695196054061056 |